Discovery of VEGFR‐2 Inhibitors From Leonurus japonicus via Integrated Genetic Authentication, Molecular Networking, and In Silico Analysis
Archiv der Pharmazie · 2026-08 · 359 (8)
DOI: 10.1002/ardp.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 13.08.2026. Verfasst von Thiyagarajan Raviraj und 16 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Angiogenesis Inhibitors, Leonurus, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, Drug Development and Value Creation Research Center, Kaohsiung Medical University, Taiwan, Kaohsiung Medical University Research Foundation, Taiwan.
Abstract (Originalsprache)
Angiogenesis, regulated by vascular endothelial growth factor (VEGF), is crucial in tumor growth, metastasis, and inflammation. Leonurus japonicus Houtt., a traditional Chinese herb, was investigated for its anti‐angiogenic potential. DNA sequencing confirmed its identity, distinguishing it from the common morphological misidentification with Leonurus sibiricus by the public. Using UHPLC‐MS/MS and GNPS (Global Natural Products Social) molecular networking on the active methanol partition, over 6000 nodes were grouped into 273 clusters. Diterpenoids and flavonoids were targeted. Six compounds were successfully isolated from L. japonicus , including four labdane‐type diterpenoids ( 1 – 4 ) and two flavonoids ( 5 , 6 ) using column chromatography. Compound 1 , (–)‐8 S ‐acetoxy‐15,16‐epoxy‐8,9‐seco‐13(16),14‐labdadiene, was a new stereoisomer, while Compound 6 , nevadensin, was reported for the first time from this species. Compounds were characterized by NMR, ESI‐MS, and ECD. At 50 μM, Compounds 1 , 4 , and 5 exhibited inhibitory effects in endothelial progenitor cell (EPC) tube formation. Molecular docking and dynamics simulations supported this anti‐angiogenic activity. Compound 1 showed the highest VEGFR‐2 binding affinity (−9.24 kcal/mol), comparable to sunitinib (−9.52 kcal/mol), further verified by an immunoblotting assay. This study demonstrated the successful integration of GNPS and bioactivity‐guided isolation for identifying natural VEGFR‐2 inhibitors. Our findings highlight Compounds 1 and 4 as promising lead candidates for anti‐angiogenic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- Institute of Biomedical Sciences, MacKay Medical University, Taiwan.
- Department of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu City, Taiwan.
- School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien City, Hualien County, Taiwan.
- Department of Medicine, MacKay Medical University, New Taipei City, Taiwan.
ORCID-Profile: Thiyagarajan Raviraj, Chen-Lin Yu, Aekkhaluck Intharuksa, Vidya Febrasca Tenderly, Yen Chi Loo, Shih-Wei Wang, Kartiko Arif Purnomo, Soundar Rajan Kulandhaivel, Sedin Renadi, Stephen Lirio, Yuan-Bin Cheng, Yu-Liang Yang, Tsong-Long Hwang, Fang-Rong Chang, Michal Korinek
Förderung
- National Science and Technology Council, Taiwan
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Taiwan
- Kaohsiung Medical University Research Foundation, Taiwan
- NSYSU-KMU joint research project, Taiwan
Zitieren
APA
Raviraj, T., Yu, C. L., Intharuksa, A., Lai, S. C., Tenderly, V. F., Loo, Y. C., Chen, P. W., Wang, S. W., Purnomo, K. A., Kulandhaivel, S. R., Renadi, S., Lirio, S., Cheng, Y. B., Yang, Y. L., Hwang, T. L., Chang, F. R., & Korinek, M. (2026). Discovery of VEGFR‐2 Inhibitors From Leonurus japonicus via Integrated Genetic Authentication, Molecular Networking, and In Silico Analysis. Archiv der Pharmazie, 359(8). https://doi.org/10.1002/ardp.70249
Vancouver
Raviraj T, Yu CL, Intharuksa A, Lai SC, Tenderly VF, Loo YC, et al. Discovery of VEGFR‐2 Inhibitors From Leonurus japonicus via Integrated Genetic Authentication, Molecular Networking, and In Silico Analysis. Archiv der Pharmazie. 2026;359(8). doi:10.1002/ardp.70249
BibTeX
@article{Raviraj2026,
author = {Raviraj, Thiyagarajan and Yu, Chen-Lin and Intharuksa, Aekkhaluck and Lai, Shang-Chih and Tenderly, Vidya Febrasca and Loo, Yen Chi and Chen, Pin-Wei and Wang, Shih-Wei and Purnomo, Kartiko Arif and Kulandhaivel, Soundar Rajan and Renadi, Sedin and Lirio, Stephen and Cheng, Yuan-Bin and Yang, Yu-Liang and Hwang, Tsong-Long and Chang, Fang-Rong and Korinek, Michal},
title = {Discovery of VEGFR‐2 Inhibitors From Leonurus japonicus via Integrated Genetic Authentication, Molecular Networking, and In Silico Analysis},
journal = {Archiv der Pharmazie},
year = {2026},
volume = {359},
number = {8},
doi = {10.1002/ardp.70249}
}
EUVIMED